# MAML2

Source: https://onco.cc/targets/maml2/  
OnCo record `maml2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.

## Summary

Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3.

Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes literature 0.91, affected pathway 0.94, genetic association 0.31, somatic mutation 0.89). IntOGen calls it a driver in 3 cohorts (0 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Lung Squamous Cell Carcinoma, Vulva/Vagina.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: mastermind like transcriptional coactivator 2; Mastermind-like protein 2; KIAA1819; MAM3
- Tags: cancer-genes-wave
- Symbol: MAML2
- Class: tumor-suppressor
- Biology: Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3. Location: Nucleus speckle (UniProt). Locus 11q21 (HGNC).
- Where found: Lung cancer: Open Targets association 0.60 with lung cancer (MONDO_0008903); Vulvar cancer: IntOGen driver in 1 cohort (VULVA); Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254); Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898); Mucoepidermoid carcinoma: Open Targets association 0.58 with mucoepidermoid carcinoma (MONDO_0003036); Non-small-cell lung cancer: Open Targets association 0.51 with non-small cell lung carcinoma (MONDO_0005233); IntOGen driver in 1 cohort (LUSC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:16259: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16259
- UniProt Q8IZL2: https://www.uniprot.org/uniprotkb/Q8IZL2/entry
- NCBI Gene 84441: https://www.ncbi.nlm.nih.gov/gene/84441
- Ensembl ENSG00000184384: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184384

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mucoepidermoid carcinoma](https://onco.cc/cancers/mucoepidermoid-carcinoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)

---
JSON: https://onco.cc/api/v1/entities/maml2.json